Last reviewed · How we verify

Gadoteric Acid Meglumine Salt

The Central Hospital of Lishui City · FDA-approved active Small molecule

Gadoteric Acid Meglumine Salt is a Gadolinium-based contrast agent Small molecule drug developed by The Central Hospital of Lishui City. It is currently FDA-approved for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging.

Gadoteric acid meglumine salt is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.

Gadoteric acid meglumine salt is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues. Used for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging.

At a glance

Generic nameGadoteric Acid Meglumine Salt
SponsorThe Central Hospital of Lishui City
Drug classGadolinium-based contrast agent
TargetWater proton relaxation (T1 relaxation time)
ModalitySmall molecule
Therapeutic areaDiagnostic Imaging
PhaseFDA-approved

Mechanism of action

Gadoteric acid is a macrocyclic gadolinium chelate complex that distributes in the extracellular space and increases signal intensity in T1-weighted MRI images. The paramagnetic gadolinium ion alters the relaxation properties of nearby water molecules, enabling improved visualization of anatomical structures and pathological lesions during MRI examinations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Gadoteric Acid Meglumine Salt

What is Gadoteric Acid Meglumine Salt?

Gadoteric Acid Meglumine Salt is a Gadolinium-based contrast agent drug developed by The Central Hospital of Lishui City, indicated for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging.

How does Gadoteric Acid Meglumine Salt work?

Gadoteric acid meglumine salt is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.

What is Gadoteric Acid Meglumine Salt used for?

Gadoteric Acid Meglumine Salt is indicated for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging.

Who makes Gadoteric Acid Meglumine Salt?

Gadoteric Acid Meglumine Salt is developed and marketed by The Central Hospital of Lishui City (see full The Central Hospital of Lishui City pipeline at /company/the-central-hospital-of-lishui-city).

What drug class is Gadoteric Acid Meglumine Salt in?

Gadoteric Acid Meglumine Salt belongs to the Gadolinium-based contrast agent class. See all Gadolinium-based contrast agent drugs at /class/gadolinium-based-contrast-agent.

What development phase is Gadoteric Acid Meglumine Salt in?

Gadoteric Acid Meglumine Salt is FDA-approved (marketed).

What are the side effects of Gadoteric Acid Meglumine Salt?

Common side effects of Gadoteric Acid Meglumine Salt include Headache, Dizziness, Nausea, Injection site reactions, Gadolinium retention (rare).

What does Gadoteric Acid Meglumine Salt target?

Gadoteric Acid Meglumine Salt targets Water proton relaxation (T1 relaxation time) and is a Gadolinium-based contrast agent.

Related